Glaukos stock gets a stronger 2026 outlook after Q3 growth

Published on 11/05/2026 at 03:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glaukos stock trades at 219.00 euros in late Lang and Schwarz trading. The company raised its 2026 sales outlook after record third-quarter growth.

Glaukos raises growth expectations

Third-quarter sales rose 58 percent year over year to USD 211.0 million.
Management raised 2026 sales guidance and introduced preliminary 2027 guidance of USD 1 billion.
Glaukos returned to GAAP profitability in the quarter as its glaucoma and corneal franchises expanded.

GKOS, US3773221029, Illustration mit AI erstellt.

Glaukos reported record third-quarter sales on October 28, 2026, and raised its full-year outlook. The ophthalmic medical technology company said in its financial results release that revenue reached USD 211.0 million for the quarter ended September 30, up 58 percent from a year earlier.

The real-time quote of Glaukos stock was 219.00 euros on Lang and Schwarz at 11:00 p.m. CET on Wednesday, November 4. The quote is shown without a daily comparison because a matching Xetra close was not established.

Sales growth broadens across franchises

U.S. Glaucoma sales rose 47 percent year over year to USD 118.6 million. Corneal Health sales increased 154 percent to USD 59.0 million, with the company highlighting continued commercial momentum for iDose TR and Epioxa.

GAAP net income was USD 2.0 million, compared with a net loss of USD 16.2 million in the prior-year quarter. Non-GAAP net income was USD 28.5 million and non-GAAP diluted earnings per share were USD 0.47; the company also reported a non-GAAP gross margin of approximately 88 percent.

Guidance points to another expansion year

Glaukos raised its 2026 net sales guidance to USD 775 million to USD 785 million from the previous range of USD 680 million to USD 700 million. Management also introduced preliminary 2027 net sales guidance of USD 1 billion, based on the expected commercial rollout of its glaucoma and corneal therapies.

The company ended September with approximately USD 339.8 million in cash, cash equivalents, short-term investments and restricted cash, and reported no debt. Investors will next look for the quarterly filing and further detail on reimbursement, product adoption and the path to sustained profitability.

Glaukos serves eye-care markets

Glaukos develops and commercializes pharmaceutical and medical technology products for glaucoma, corneal disorders and retinal diseases. Its portfolio includes micro-invasive glaucoma surgery devices, the iDose TR intracameral implant and a corneal cross-linking therapy. The company sells through a direct sales organization and distributors in the United States and international markets and is headquartered in San Clemente, California.